Effector Therapeutics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Effector Therapeutics prevailing Real Value cannot be determined due to lack of data. The current price of Effector Therapeutics is $0.0. Our model computes the value of Effector Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 23.71 %, shares owned by insiders of 2.90 %, and Current Valuation of (4.52 M) as well as analyzing its technical indicators and probability of bankruptcy.
Effector Therapeutics Total Value Analysis
Effector Therapeutics is currently anticipated to have valuation of (4.52 M) with market capitalization of 846.79 K, debt of 19.45 M, and cash on hands of 41.04 M. The negative valuation of Effector Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Effector Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.52 M) | 846.79 K | 19.45 M | 41.04 M |
Effector Therapeutics Asset Utilization
One of the ways to look at asset utilization of Effector is to check how much profit was generated for every dollar of assets it reports. Effector Therapeutics shows a negative utilization of assets of -0.83 percent, losing $0.008333 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Effector Therapeutics shows how discouraging it operates for each dollar spent on its assets.Effector Therapeutics Ownership Allocation
Roughly 73.39 percent of Effector Therapeutics outstanding shares are held by general public with 2.9 (percent) owned by insiders and only 23.71 % by other corporate entities.Effector Therapeutics Profitability Analysis
Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M).Effector Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Effector Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.2 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |